A Peptide Primer for 2026
What peptides actually are, how the main categories work, and what the evidence honestly looks like
title: "A Peptide Primer for 2026" dek: "What peptides actually are, how the main categories work, and what the evidence honestly looks like" slug: "core-peptide-primer" date: "2026-04-14" tags: ["peptides", "education"]
Peptides are everywhere in wellness conversations right now, and the signal-to-noise ratio is poor. Clinics promise regeneration. Fitness forums trade dosing spreadsheets. And most people asking reasonable questions — What exactly is a peptide? Does any of this work? Is it safe? — find themselves buried in hype or jargon.
This article is a plain-language foundation. We'll cover what peptides are biologically, walk through the main therapeutic categories, describe who might benefit and who should stay away, and be honest about where the evidence is solid versus where it is still thin.
What Is a Peptide?
A peptide is a short chain of amino acids — the same building blocks that make proteins. The distinction is size: by convention, chains under roughly 50 amino acids are called peptides; longer chains fold into full proteins. Your body already produces thousands of peptides naturally. They serve as signaling molecules, hormones, and structural components in virtually every tissue.
Because peptides are amino acid sequences, they are chemically similar to food. They don't accumulate in fat tissue the way small-molecule drugs or steroids can. They tend to act on specific receptors, which is part of why researchers find them interesting: selectivity means, in principle, fewer off-target effects.
That selectivity also means peptides are fragile. Most are destroyed by digestive enzymes, which is why therapeutic peptides — those used at meaningful biological doses — are typically injected rather than swallowed. (A few acid-stable versions exist as oral capsules, but their systemic absorption is limited and context-specific.)
The Main Categories
Growth Hormone Secretagogues (GHS)
These peptides don't deliver synthetic growth hormone directly. Instead, they nudge the pituitary gland to release more of your own. This is an important distinction. Direct GH injection overrides the body's feedback loops and carries significant risks. Secretagogues work within the existing regulatory system.
There are two main classes:
GHRH analogs (like CJC-1295 / Mod-GRF 1-29) mimic growth hormone-releasing hormone, the signal your hypothalamus sends when it wants the pituitary to pulse GH. They amplify an existing signal.
GHRPs — ghrelin mimetics (like ipamorelin) bind to a separate receptor that also stimulates GH release, by mimicking ghrelin. Ipamorelin is considered the most selective of the GHRPs, meaning it appears to stimulate GH release without meaningfully raising cortisol, prolactin, or other hormones that less-selective GHRPs can disturb.
The two classes are often combined because they work through different mechanisms and have a synergistic effect — roughly fivefold greater GH release when paired than either produces alone, according to clinical pharmacology research reviewed by Dr. William Seeds and colleagues at the SSRP Institute.
Natural GH secretion declines roughly 15 percent per decade after age 30, with the drop becoming more pronounced after 50. Secretagogues are primarily used to restore more youthful pulsatile patterns rather than to achieve supraphysiologic levels.
Repair and Tissue Peptides
BPC-157 (Body Protection Compound) is a 15-amino-acid sequence originally derived from a gastroprotective protein found in gastric juice. It has been studied most rigorously for gastrointestinal conditions — a Phase II randomized controlled trial in ulcerative colitis patients (using the clinical designation PL 14736) demonstrated statistically significant improvement in the Disease Activity Index compared to placebo, with excellent tolerability. Animal research on musculoskeletal healing is extensive, though translation to humans has not been fully established.
Thymosin Beta-4 (TB-500) is a 43-amino-acid peptide involved in actin regulation, wound healing, and angiogenesis. It exists naturally in most human tissues. Different fragments of the molecule appear responsible for different effects: fragments 1-4 have anti-inflammatory properties; fragments 17-23 are associated with cell migration and healing; fragments 40-43 show cardiac-protective activity in preclinical studies. It is in various stages of clinical development under the name RGN-352 (injectable) for cardiac applications and RGN-259 (eye drops) for ocular surface disease, the latter having completed Phase 3 trials.
Metabolic Peptides
Tesamorelin is a stabilized GHRH analog with the most robust clinical evidence in its category — it is FDA-approved for reducing visceral (deep abdominal) fat in HIV-associated lipodystrophy. Off-label interest in tesamorelin centers on its demonstrated ability to reduce visceral adipose tissue and improve lipid metabolism more broadly.
GLP-1 analogs like semaglutide and tirzepatide are by now familiar from headline coverage of their weight-loss applications. These are peptide-based drugs, FDA-approved, with large randomized trial bases. They are not "gray zone" compounds — they are regulated medications that require prescriptions and medical oversight.
Cognitive and Neuroprotective Peptides
Selank is a synthetic analog of tuftsin, an immune peptide. It is used in Russia as an approved anxiolytic and has been studied for generalized anxiety disorder, mood regulation, and cognitive enhancement. Evidence in Western peer-reviewed literature is limited; most trials come from Russian clinical research.
Semax is an ACTH-derived peptide used intranasally. It appears to elevate brain-derived neurotrophic factor (BDNF) in preclinical models and is similarly approved in Russia for ischemic stroke recovery and cognitive decline, though large Western RCTs are absent.
Longevity-Oriented Peptides
Epithalon (Epitalon) is a tetrapeptide derived from the pineal gland peptide epitalamin. It has been studied primarily in Russian literature for telomere-related effects and circadian regulation. Human clinical data exist but are not extensive by Western regulatory standards; the strongest use case in the literature is immune function support in elderly populations.
MOTS-c and Humanin are mitochondrial-derived peptides with emerging research suggesting roles in metabolic regulation and cellular protection. They represent genuinely early-stage science — interesting mechanistic hypotheses with limited clinical translation as of 2026.
Who Might Benefit
The honest answer is: it depends heavily on which peptide and why.
The strongest case for therapeutic use exists in adults who have documented deficiencies or age-related declines in the relevant pathways, who are working with a physician, and who have realistic expectations. A 58-year-old with low IGF-1 on lab work, metabolic concerns, and poor sleep may be a reasonable candidate for a supervised GH secretagogue protocol. Someone with a persistent soft tissue injury that hasn't responded to conventional care may have reason to explore BPC-157 under a physician's guidance — especially given its human safety data. Someone with confirmed metabolic syndrome might have a meaningful conversation about tesamorelin or GLP-1 agonists with their doctor.
Peptides are not magic. Clinicians working in this space consistently acknowledge that some compounds have extensive human testing and FDA approval, while others have only rodent studies or theoretical applications. That honest spectrum matters.
Who Should Be Cautious
Anyone with a history of cancer or active malignancy should approach certain peptides — particularly TB-500 and GH secretagogues — with significant caution or avoid them entirely, as elevated TB4 expression has been associated with increased metastatic activity, and supraphysiologic IGF-1 elevation carries theoretical proliferative risk.
People with mast cell activation syndrome (MCAS) should be aware that the 17-23 fragment of TB-500 has been shown to induce mast cell exocytosis.
People with hypermobility disorders (like Ehlers-Danlos syndrome) should use caution with TB-500, as it may increase tissue flexibility in ways that worsen joint instability.
Anyone on immunosuppressants, insulin, or hormonal therapies should discuss interactions with a prescribing physician before adding peptides.
Older adults on multiple medications face the greatest pharmacokinetic complexity. Nothing in the peptide space has been tested extensively in people over 70 taking five or more drugs simultaneously.
The Regulatory Landscape in Plain Terms
Some peptides are fully FDA-approved drugs: insulin, semaglutide, tirzepatide, tesamorelin (for its approved indication), and bremelanotide (PT-141 for hypoactive sexual desire disorder) among others. If your doctor writes a prescription and a licensed pharmacy fills it, you are operating in the regulated system.
Most peptides discussed in longevity and repair contexts occupy a different legal space. Compounds like BPC-157, ipamorelin, and CJC-1295 can be prescribed by physicians in some jurisdictions and compounded by licensed compounding pharmacies — that is a legal pathway for off-label clinical use. They can also be purchased from "research chemical" suppliers, which is generally legal to possess in the US but exists in a regulatory gray zone: the products are often labeled "not for human consumption," quality control is unverified, and there is no recourse if something goes wrong.
The practical implication: the route of access matters as much as the compound itself. A compounding pharmacy operating under a physician's order is not the same risk environment as an online research chemical vendor. Both are legal in most US states, but they are not equivalent.
Safety & Disclaimer
The information in this article is educational. It is not medical advice, and it is not a substitute for a consultation with a qualified physician.
Peptide therapy is an evolving area of medicine. The evidence base varies enormously by compound — some peptides have robust human clinical trial data; others are supported primarily by animal studies or observational reports. Dosing, cycling, and monitoring parameters that appear appropriate in one clinical context may be inappropriate for a specific individual.
If you are over 50, taking prescription medications, managing a chronic condition, or have a personal or family history of cancer or hormone-sensitive disease, please discuss any interest in peptides with your physician before taking any action. Many forward-thinking clinicians are familiar with this landscape and can help you evaluate options in the context of your full health picture.